BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

950 related articles for article (PubMed ID: 19624495)

  • 1. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients.
    Hillebrand U; Suwelack BM; Loley K; Lang D; Reuter S; Amler S; Pavenstädt H; Hausberg M; Büssemaker E
    Transpl Int; 2009 Nov; 22(11):1073-80. PubMed ID: 19624495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
    Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
    J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood pressure control in kidney transplantation: therapeutic implications.
    Premasathian NC; Muehrer R; Brazy PC; Pirsch JD; Becker BN
    J Hum Hypertens; 2004 Dec; 18(12):871-7. PubMed ID: 15318162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants and patterns of renin-angiotensin system inhibitors' prescription in the first year following kidney transplantation.
    Thilly N; Bayat S; Alla F; Kessler M; Briançon S; Frimat L
    Clin Transplant; 2008; 22(4):439-46. PubMed ID: 18318741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis.
    Fang W; Oreopoulos DG; Bargman JM
    Nephrol Dial Transplant; 2008 Nov; 23(11):3704-10. PubMed ID: 18567695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report.
    Opelz G; Zeier M; Laux G; Morath C; Döhler B
    J Am Soc Nephrol; 2006 Nov; 17(11):3257-62. PubMed ID: 17035607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
    Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of antihypertensive prescription and associated blood pressure control in Japan.
    Mori H; Ukai H; Yamamoto H; Saitou S; Hirao K; Yamauchi M; Umemura S
    Hypertens Res; 2006 Mar; 29(3):143-51. PubMed ID: 16755149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-angiotensin system blockade and kidney transplantation: a longitudinal cohort study.
    Hernández D; Muriel A; Abraira V; Pérez G; Porrini E; Marrero D; Zamora J; González-Posada JM; Delgado P; Rufino M; Torres A
    Nephrol Dial Transplant; 2012 Jan; 27(1):417-22. PubMed ID: 21622985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients.
    Suwelack B; Kobelt V; Erfmann M; Hausberg M; Gerhardt U; Rahn KH; Hohage H
    Transpl Int; 2003 May; 16(5):313-20. PubMed ID: 12759722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
    Montanaro D; Gropuzzo M; Tulissi P; Vallone C; Boscutti G; Mioni R; Risaliti A; Baccarani U; Adani GL; Sainz M; Bresadola F; Mioni G
    Transplant Proc; 2005 Mar; 37(2):991-3. PubMed ID: 15848600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Assessment of antihypertensive monotherapies effectiveness by home blood pressure self-measurement in hypertensive patients].
    Hanon O; Laroche P; Vidal JS; Pannier B; Postel-Vinay N; Vaisse B; Girerd X
    Ann Cardiol Angeiol (Paris); 2012 Jun; 61(3):218-23. PubMed ID: 22695025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy?
    Courtney AE; McNamee PT; Nelson WE; Maxwell AP
    Nephrol Dial Transplant; 2006 Dec; 21(12):3550-4. PubMed ID: 16968729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period.
    Formica RN; Friedman AL; Lorber MI; Bia MJ
    Transplant Proc; 2004 Nov; 36(9):2675-8. PubMed ID: 15621121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
    Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
    Katayama S; Yagi S; Yamamoto H; Yamaguchi M; Izumida T; Noguchi Y; Inaba M; Inukai K
    Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
    Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
    Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of long-term beneficial effects on blood pressure after percutaneous transluminal renal angioplasty in atherosclerotic renal artery stenosis.
    Alhadad A; Mattiasson I; Ivancev K; Lindblad B; Gottsäter A
    Int Angiol; 2009 Apr; 28(2):106-12. PubMed ID: 19367240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.